Submitted by mphilemon@resea... on Fri, 01/07/2011 - 12:33
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview
with Rafael Fonseca, MD (12/22/10)
Vesole DH et al. Lenalidomide plus low-dose dexamethasone (Ld): Superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD). Proc ASH 2010;Abstract 308.
Dr Fonseca is Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.
